Group sales -3% driven by expected decline in coVID-19 testing 

.Strong Pharma performance (+9%) driven by ongoing portfolio rejuvenation

. Good Diagnostics base business growth (+4%) 

. cOVID-19 sales decline in line with FY 2023 expectations 

Growth supported by key products and strong launches 

. Pharma key products Vabysmo, Ocrevus, Hemlibra,Evrysdi, Tecentrig, Perjeta, Phesgo and Polivy continuing to grow strongly

 .Key Fharma approvals:Polivy in 1L DLBCL in the US,Hemlibra in moderate hem A in the EU, Columvi (glofitamab) in 3L+ DLBCL in Canada

. Diagnostics: launches of new tests in oncology, navify Algorithm Suite and navify Marketplace

Update on pipeline newsflow in 2023 

.Positive Phase ll results for Tecentriq + Avastin in adjuvant HCC and crovalimab in PNH achieved

.Pharma: 14 upcoming late-stage read-outs incl.2NMEs(tragolumab, SRP-900) and important line extensions for Ocrevus,Tecentrig,Venclexta,TNKase,Alecensa and Lunsumio

. Diagnostics: CCM Vertical, LightCycler Pro,Anti-HEV lgG/IgM,HBeAg Quant, and lL-6 Neonatal sepsis